Physician profile
David R Powers
NPI 1548265812
$34,647.75
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $6,906 · 2021: $805 · 2022: $1,311 · 2023: $1,245 · 2024: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29,312.68 | 2019-2023 | Ultomiris |
| Amgen INC. | $1,064.55 | 2019-2024 | Tavneos, Parsabiv, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $844.23 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $828.36 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $361.68 | 2019-2024 | Rayaldee |
| Nxstage Medical, INC. | $300.16 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $296.38 | 2019-2023 | Farxiga |
| Horizon Therapeutics Plc | $287.03 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $198.42 | 2022-2023 | Tarpeyo |
| Vifor Pharma, INC. | $172.61 | 2019-2022 | |
| Aspira Women'S Health INC | $161.77 | 2022 | |
| Akebia Therapeutics INC | $153.42 | 2019-2024 | Auryxia, Vafseo |
| Daiichi Sankyo INC. | $113.18 | 2021-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $102.07 | 2021-2022 | |
| Tesaro, INC. | $101.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $85.33 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $79.31 | 2019-2024 | |
| Eisai INC. | $71.95 | 2022 | |
| Fresenius USA Marketing, INC. | $33.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.58 | 2024 | |
| Lilly USA, LLC | $21.90 | 2024 | Jardiance |
| Travere Therapeutics, INC. | $16.30 | 2023 | |
| Mallinckrodt Enterprises LLC | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.